Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome

Hamostaseologie

Volumn 21, Issue 2, 2001, Pages 77-81

  Finazzi, G ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Antiphospholipid antibodies; Lupus anticoagulants; Randomized clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 0034929261     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619507     Document Type: Review

References (29)

1. Guidelines on the investigation and management of the antiphospholipid syndrome
2. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian Registry
3. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE)
4. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients
5. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
6. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia
7. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke
8. Anticardiolipin antibodies in an unselected stroke population
9. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies
10. The management of thrombosis in the antiphospholipid syndrome
11. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependendent and β2-glycoprotein I-dependent antiphospholipid antibodies
12. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment
13. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
14. Answers to the antiphospholipid-antibody syndrome?
15. Thrombosis in the antiphospholipid syndrome
16. Thrombosis in the antiphospholipid syndrome
17. Antiphospholipid antibodies and venous thromboembolism
18. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing thrombosis
19. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
20. Conventional intensity may be as effective as high intensity oral anticoagulation in the antiphospholipid syndrome
21. Management of thrombosis in the antiphospholipid syndrome
22. Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: The WAPS project
23. The WAPS (Warfarin in AntiPhospholipid Syndrome) study. Update and preliminary results
24. A comparison of observational studies and randomized, controlled trials
25. Randomized, controlled trials, observational studies and the hierarchy of research design
26. Randomized trials or observational tribulations?
27. The feasibility of a collaborative double-blind study using an anticoagulant
28. The WARSS-APASS collaborative study: Baseline aPL prevalence
29. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies